Pharmacotherapeutic profile of users and expenditure on high-cost drugs in São Leopoldo, Rio Grande do Sul State, Brazil, 2014*

doi: 10.5123/S1679-49742017000400008

Abstract

Objective: to describe the pharmacotherapeutic profile of users of the Specialized Program for Pharmaceutical Assistance, and to measure the expenditure on the most prevalent and the most expensive medications. Methods: descriptive study conducted in São Leopoldo-RS, Brazil, with secondary data regarding information about requests accepted in 2014, through administrative proceedings; delivery notes of the State Health Department/RS were used to assess the costs. Results: 1,528 users were included in the study, mostly women (56.7%), and the average age was 52 years (standard deviation=17.9); the most frequent diagnoses were allergic asthma (17.1%), chronic kidney disease (11.5%) and rheumatoid arthritis (8.4%); the most prevalent drug was budesonide+formoterol fumarate (18.3%); among the most prevalent drugs, the highest total monthly expense was with epoetin alfa (BRL37,922.34) and among the most expensive drugs, infliximab (BRL72,503.28). Conclusion: the data show the importance of the Specialized Program for Pharmaceutical Assistance in the high-cost treatment of highly prevalent.

Keywords: Drug Utilization; Drug Costs; Chronic Disease; Pharmaceutical Services; Epidemiology, Descriptive.

*Manuscript based on Mariani Sopela's Master's thesis, entitled 'Profile of users of the Specialized Program for Pharmaceutical Assistance drugs in the municipality of São Leopoldo, RS', presented to the Post Graduate Program in Public Health of the Vale do Rio dos Sinos University (UNISINOS), São Leopoldo-RS, in 2015.
Introduction

In Brazil, the National Health Policy (NHP) establishes the conditions for the promotion, protection and recovery of health, as well as the organization and management of services, based on the principles of universality, equity and comprehensiveness of health care in the Brazilian National Health System (SUS). The National Medicines Policy was approved in 1998, as an essential part of the NHP. It aimed at ensuring safety, efficacy and quality of medicines, promote their rational use and the population access to those medicines considered essential. The adoption of the National List of Essential Drugs (Rename) and the realignment of Pharmaceutical Assistance (FA) are among the main guidelines of this policy.\(^1\)

The current Rename comprises the set of medicines provided by SUS through funding programs by FA. The expanded concept of essentiality aims at guaranteeing a comprehensive medical treatment. The realignment of FA aims at implementing activities to promote access to essential drugs, based on a decentralized management, promotion of rational use, and optimization and efficacy of the distribution system in the public sector.\(^1\)

The National Policy on Pharmaceutical Assistance approved in 2004 is a guide for public policy for the development of sector policies, considering medicines essential inputs.\(^1\)

Also in accordance with health policies, the National Policy on Pharmaceutical Assistance approved in 2004 is a guide for public policy for the development of sector policies, considering medicines essential inputs, and aiming at access and their rational use, as well as at the decentralization of actions.\(^1\) Nowadays, FA funding is divided as follows: Primary Component of Pharmaceutical Assistance, comprising medicines used in primary health care; Strategic Component of Pharmaceutical Assistance, for financing medicines for communicable diseases and/or diseases of high impact on health, such as AIDS and tuberculosis, among others; and Specialized Component of Pharmaceutical Assistance,\(^1\) object of this study.

The Specialized Component of Pharmaceutical Assistance is an important strategy which aims at ensuring access to medicines at SUS for the treatment of diseases, both rare and of high prevalence, since there was a prescription for the use of high-cost-per-unit drugs or those whose cost becomes overly expensive due to a chronic treatment. The major challenge of the policy of access to medicines when it comes to this Component, which has a growing number of users each year, is the high financial impact.\(^3,5\) In 2003, the expenditures with its drugs were approximately BRL516 million; in 2014, these expenses reached BRL4.9 billion, a 9.5 times growth.\(^6\)

However, many of these expenditures could be avoided with a full monitoring of individuals, since they are assisted at primary health care.\(^7,8\) Hence, the identification of the most frequent diseases within the Specialized Component among users may not only help the guidance of actions with emphasis on pharmaceutical assistance and pharmacotherapeutic monitoring, but also subsidize actions aiming at modifying the historical profile of these diseases. Studies on this subject can contribute to a more effective FA planning, providing elements to the decision-makers in the planning of actions and in the supply of high-cost drugs.

The objective of this study was to describe the pharmacotherapeutic profile of users of the Specialized Component drugs in the municipality of São Leopoldo, Rio Grande do Sul State, Brazil, and to measure expenditures on the most prevalent drugs and those with major financial impact.

Methods

This is a descriptive study conducted in the municipality of São Leopoldo-RS, with secondary data from the Medicines Management System (AME®) provided by Rio Grande do Sul State Health Department (SES/RS).

São Leopoldo-RS, a municipality located in the Brazilian South region, had 214,087 inhabitants in 2010, a population density of 2,083.82 inhabitants/km\(^2\) and a human development index (HDI) of 0.739.\(^7\) At the time of this study, the municipality had 19 primary health care units (PHU), of which nine covered the Family Health Strategy (FHS), and there was one Central Municipal Pharmacy, dispenser of Specialized Component drugs.

Data from all users of Specialized Component drugs with a request granted through administrative proceedings from January/2014 to December/2014 were included. Considering that the users received those medicines every month, we used the information about their last dispensing.
The study variables were defined based on data provided by the AME® system:
- sex (male, female);
- age (based on birth date and organized in age groups, in years: 0-19; 20-39; 40-59; 60 or more);
- place of household (neighborhood, identified from the address and classified according to the presence of PHU with or without FHS);
- morbidities (according to the International Statistical Classification of Diseases and Related Health Problems – 10th Revision [ICD-10], subsequently grouped into chapters); and
- medicines (classified according to the active ingredient, dosage and dosage form).

The statistical program Stata 11.0 (Stata Corp., College Station, United States of America) was used for the analysis. Morbidities, according to ICD-10 and its chapters, were stratified by sex, age group and place of household, with or without FHS. Prevalence was presented with its respective 95% confidence intervals (95%CI) and analyzed by the chi-squared test, for heterogeneity of proportions and linear trend, adopting a statistical significance level of 5%.

The drugs costs were obtained from SES/RS delivery notes, updated for the year 2015, up to April. These costs were determined for both the most prevalent and the most expensive drugs. In order to determine the most expensive drugs, those with the highest financial impact were selected in the literature, considering the cost of the pharmacological treatment per individual per month. Each user monthly expenses were determined for each drug, then summed, and this result divided by the number of users, obtaining the average monthly expenses per individual. The total monthly expense was obtained by summing the users’ monthly expenses for each drug.

This research project was approved by the Ethics Research Committee of Vale do Rio dos Sinos University (UNISINOS): Resolution No. 143 dated October 14th, 2014. Rio Grande do Sul State Health Department allowed the use of data; the ethical issues of confidentiality for the users’ names and the commitment in the publication of results were also observed.

Results

A total of 1,528 users of Specialized Component drugs were included, mostly women (56.7%), the average age was 52 years (standard deviation = 17.9), and almost half of users (44.1%) were residents in neighborhoods with PHU/FHS.

The most prevalent diagnoses are grouped in the chapters on diseases of the respiratory system (18.7%) and diseases of the musculoskeletal and connective tissue (17.3%). There was a higher prevalence of diseases of the musculoskeletal system and connective tissue, and diseases of the blood and blood-forming organs in women compared to men. For men, mental and behavioral disorders were more prevalent (Table 1).

Diseases of the respiratory system and genitourinary system were more prevalent among the elderly, whilst diseases of the musculoskeletal system and connective tissue and certain infectious and parasitic diseases were more frequent in the age group from 40 to 59 years. Diseases of the digestive system and mental disorders were more prevalent between 20 and 39 years, and endocrine, nutritional and metabolic diseases, diseases of blood and blood-forming organs and diseases of the nervous system were more frequent in those aged 0 to 19 years (Table 2).

Diseases of the genitourinary system were more prevalent in FHS neighborhoods than in neighborhoods without the presence of these teams (14.7% versus 10.5%). In the non-FHS neighborhoods, higher prevalence of mental and behavioral disorders were observed in comparison with FHS neighborhoods (8.4% vs. 4.3%); the same occurred among diseases of the nervous system (10.5% vs. 7.7%) (data not presented in the table).

Out of the 146 reported morbidities, 15 (10.3%) represented the most frequent diagnoses. Among users, 95.0% had one and 4.5% had two morbidities. The most prevalent diagnoses were predominantly allergic asthma (17.1%), chronic kidney disease stage 5 (11.5%), kidney transplanted status (7.6%) and chronic viral hepatitis C (6.0%). Women presented higher proportions – compared to men – of other seropositive rheumatoid arthritis, seronegative rheumatoid arthritis, hyperprolactinemia and lupus erythematosus. Chronic kidney disease stage 5, viral hepatitis C and paranoid schizophrenia were predominant in men (Table 3).

Predominantly allergic asthma and chronic kidney disease stage 5, were more prevalent in the elderly. The diagnosis of kidney transplanted status and
Table 1 – Classification of users of the Specialized Component of Pharmaceutical Assistance drugs (N=1,528), total and stratified by sex, according to ICD-10 codes, in the municipality of São Leopoldo-RS, 2014

| ICD-10 chapters * | Users of Specialized Component drugs, by sex | p-value c |
|-------------------|---------------------------------------------|-----------|
|                   | Total: 1,528 | Females: 866 | Males: 662 |         |
|                   | % | 95%CI | % | 95%CI | % | 95%CI |
| I Certain infectious and parasitic diseases | 8.4 | 7.0;9.8 | 6.4 | 4.7;8.0 | 11.2 | 8.8;13.6 | <0.001 |
| II Neoplasms | 0.1 | 0.1;0.3 | 0.1 | 0.1;0.3 | 0.2 | 0.1;0.5 | 0.849 |
| III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | 0.9 | 0.4;1.3 | 1.4 | 0.6;2.2 | 0.2 | 0.1;0.4 | 0.009 |
| IV Endocrine, nutritional and metabolic diseases | 11.6 | 10.0;13.2 | 11.2 | 9.1;13.3 | 12.1 | 9.6;14.6 | 0.593 |
| V Mental and behavioural disorders | 6.6 | 5.4;7.9 | 3.8 | 2.5;5.1 | 10.3 | 8.0;12.6 | <0.001 |
| VI Diseases of the nervous system | 9.2 | 7.8;10.7 | 8.9 | 7.0;10.8 | 9.7 | 7.4;11.9 | 0.603 |
| VII Diseases of the eye and adnexa | 0.1 | 0.1;0.22 | 0.1 | 0.1;0.3 | 0.0 | – | 0.382 |
| IX Diseases of the circulatory system | 18.7 | 16.7;20.6 | 19.5 | 16.9;22.2 | 17.5 | 14.6;20.4 | 0.322 |
| XI Diseases of the digestive system | 6.1 | 4.9;7.3 | 6.1 | 4.5;7.7 | 6.0 | 4.2;7.9 | 0.950 |
| XII Diseases of the skin and subcutaneous tissue | 0.8 | 0.3;1.2 | 0.6 | 0.1;1.1 | 1.1 | 0.3;1.8 | 0.292 |
| XIII Diseases of the musculoskeletal system and connective tissue | 17.3 | 15.4;19.2 | 24.1 | 21.3;27.0 | 8.5 | 6.3;10.6 | <0.001 |
| XIV Diseases of the genitourinary system | 12.4 | 10.7;14.0 | 10.3 | 8.3;12.3 | 15.1 | 12.4;17.8 | 0.004 |
| XVII Congenital malformations, deformations and chromosomal abnormalities | 0.2 | 0.0;0.4 | 0.4 | 0.0;0.7 | 0.0 | – | 0.130 |
| XVIII Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | 1.3 | 0.7;1.9 | 1.5 | 0.7;2.3 | 1.1 | 0.3;1.8 | 0.449 |
| XIX Injury, poisoning and certain other consequences of external causes | 0.2 | 0.0;0.4 | 0.2 | 0.1;0.6 | 0.2 | 0.1;0.4 | 0.727 |

a) ICD-10: International Statistical Classification of Diseases and Related Health Problems – 10th Revision.
b) 95%CI: 95% confidence interval.c) p-value from a chi-squared test for heterogeneity of proportions.

paranoid schizophrenia were more frequent in the age group from 20 to 39 years, whilst chronic viral hepatitis C, among individuals aged 40 to 59 years (Table 4).

There was a higher prevalence of chronic kidney disease stage 5, in FHS neighborhoods when compared to non-FHS neighborhoods (13.4% vs. 9.9%). Higher prevalence of Alzheimer’s disease with late-onset and paranoid schizophrenia was found in non-FHS neighborhoods, compared to neighborhoods with FHS (2.5% vs. 0.7% and 5.8% vs. 3.4%, respectively) (Data not presented in the table).

A total of 2,431 drugs were collected by 1,528 users, distributed in 96 different active ingredients, and 147 forms. The most prevalent drug was budesonide+formoterol fumarate (18.3%), followed by epoetin alfa (11.5%); iron hydroxide saccharate (8.5%); azathioprine (6.6%), tacrolimus (6.0%); ribavirin (5.8%), calcitriol (5.6%); sodium mycophenolatee (5.2%); leflunomide (4.8%); and methotrexate (5.9%) (Table 5).

Among the ten most prevalent drugs, four had higher average monthly expense per individual: sodium mycophenolate, tacrolimus, epoetin alfa and calcitriol. Among the most prevalent drugs, epoetin alfa had the highest total monthly expense; and the total monthly expense resulted from the ten most prevalent drugs reached BRL144,693.63 (Table 5).

When it comes to the most expensive drugs, the drugs with the highest average monthly expense per individual were infliximab, human immunoglobulin and LAR octreotide acetate. The most expensive drug was infliximab, and the ten most expensive drugs summed a monthly expense of BRL 189,863.21 for the public health system (Table 5).
Discussion

This study showed that, in 2014, Specialized Component drugs users presented higher prevalence of diagnoses grouped in the chapters on diseases of the respiratory system, diseases of the musculoskeletal and connective tissue, and diseases of the genitourinary system, such as predominantly allergic asthma, rheumatoid arthritis and chronic renal disease stage 5, respectively. The most prevalent drug was budesonide+formoterol fumarate, which, despite the wide frequency of use, did not represent the highest expense of the system. The highest total monthly expense among the most prevalent drugs was with epoetin alfa. Among the most expensive drugs, infliximab was the most expensive per month, accounting for almost twice the total monthly expense of epoetin alfa.

The high prevalence of women who use Specialized Component drugs corroborates with the literature, which shows even higher proportions – ranging from 65.5% in a national-based historical cohort (2000-2004) to 72% in Paraná State (2010). Women report considerably more morbidities than men and, therefore, are the most frequent users of health services, thus a similar profile is expected for this Component.

Regarding the age group, the result corroborates findings from national studies with a similar population. The 2008 National Household Sample Survey (PNAD...
shows that older ages are related to the increase in the prevalence of chronic diseases and, therefore, associated with higher use of health services and medicines. With regard to the ICD-10 chapters, specifically the chapter on diseases of the respiratory system, the most frequent was allergic asthma. This finding did not stand out in the national-based study aforementioned (2000-2004). However, in this study, the high prevalence of these diseases may be associated with the climatic characteristics of the Brazilian South region, which has four well defined seasons and a humid climate, extremely cold, in the winter. Some studies with children point to climate change as the main trigger for asthmatic crises. Asthma did not differ regarding sex and age, according to another study.

The most frequent morbidities of diseases of the musculoskeletal system are in accordance with the national study; however, this confirmation was not verified for the most prevalent. In this study, the chapter is represented by rheumatoid arthritis, and in the national study cited, by osteoporosis. This difference may be explained by the fact that osteoporosis did not have a pharmacological treatment available by the Primary Component of Pharmaceutical Assistance, at that moment. Rheumatoid arthritis affected more women and adults aged over 40 years old, according to recent studies conducted in the South (2010) and Southeast (2002-2005) regions of the country. Still without a known cause, its incidence is underestimated in Brazil: according to a study conducted in 2009, only half of Brazilians with this morbidity are diagnosed, and of those, only 50% are treated. In most of these cases, the medical treatment is initiated with the drugs methotrexate, leflunomide or azathioprine, being the first considered the drug of initial choice, and all are among the most prevalent drugs according to this study. In addition, the advances in drug therapy also have some biological agents, such as infliximab and rituximab, both stood out in this study among the most expensive drugs.

Diseases of the genitourinary system, which especially include chronic kidney disease stage 5, are in accordance

**Table 3** – Classification of users of the Specialized Component of Pharmaceutical Assistance (N=1,528), total and stratified by sex, according to ICD-10 diagnoses, in the municipality of São Leopoldo-RS, 2014

| ICD-10 diagnoses | Users of Specialized Component drugs, by sex | p-value<sup>c</sup> |
|------------------|-------------------------------------------|-----------------|
|                  | Total: 1,528 | Females: 866 | Males: 662 |               |
| Predominantly allergic asthma | 17.1 | 15.2;19.0 | 18.1 | 15.6;20.7 | 15.7 | 12.9;18.5 | 0.213 |
| Chronic kidney disease stage 5 | 11.5 | 9.9;13.1 | 9.1 | 7.2;11.0 | 14.5 | 11.8;17.2 | 0.001 |
| Kidney transplant status | 7.6 | 6.3;8.9 | 7.2 | 5.4;8.9 | 8.2 | 6.1;10.2 | 0.466 |
| Chronic viral hepatitis C | 6.0 | 4.8;7.1 | 4.5 | 3.1;5.9 | 7.9 | 5.8;9.9 | 0.006 |
| Other seropositive rheumatoid arthritis | 5.1 | 4.0;6.2 | 7.5 | 5.7;9.3 | 2.0 | 0.9;3.0 | <0.001 |
| Paranoid schizophrenia | 4.7 | 3.6;5.7 | 2.2 | 1.2;3.2 | 7.9 | 5.8;9.9 | <0.001 |
| Seronegative rheumatoid arthritis | 3.3 | 2.4;4.2 | 5.2 | 3.7;6.7 | 0.9 | 0.2;1.6 | <0.001 |
| Pure hypercholesterolemia | 3.2 | 2.3;4.1 | 2.7 | 1.6;3.7 | 3.9 | 2.4;5.4 | 0.162 |
| Ankylosing spondylitis | 2.8 | 1.9;3.6 | 2.7 | 1.6;3.7 | 2.9 | 1.6;4.1 | 0.800 |
| Chronic viral hepatitis B without delta-agent | 2.4 | 1.6;3.2 | 1.9 | 0.9;2.7 | 3.2 | 1.8;4.5 | 0.095 |
| Parkinson disease | 2.2 | 1.5;3.0 | 1.6 | 0.8;2.5 | 3.0 | 1.7;4.3 | 0.065 |
| Hyperprolactinemia | 2.1 | 1.4;2.8 | 2.8 | 1.7;3.9 | 1.2 | 0.4;2.0 | 0.035 |
| Liver transplant status | 2.0 | 1.3;2.7 | 1.4 | 0.6;2.2 | 2.9 | 1.6;4.1 | 0.041 |
| Systemic lupus erythematosus with organ or system involvement | 1.9 | 1.2;2.6 | 2.9 | 1.8;4.0 | 0.6 | 0.0;1.2 | 0.001 |
| Alzheimer disease with late onset | 1.7 | 1.1;2.4 | 1.6 | 0.8;2.5 | 1.8 | 0.8;2.8 | 0.769 |
| Other diagnoses<sup>d</sup> | 31.7 | 29.3;34.0 | 34.0 | 30.8;37.1 | 28.8 | 25.2;32.2 | 0.029 |

a) ICD-10: International Statistical Classification of Diseases and Related Health Problems – 10<sup>th</sup> Revision.
b) 95%CI: 95% confidence interval.
c) p-value from a chi-squared test for heterogeneity of proportions.
d) Other diagnoses include morbidities with prevalence lower than 1.7%.---

**Epidemiol. Serv. Saude**, Brasília, 26(4), Oct-Dec 2017
Table 4 – Classification of users of the Specialized Component of Pharmaceutical Assistance (N=1,528), stratified by age group, according to ICD-10 diagnoses, in the municipality of São Leopoldo-RS, 2014

| ICD-10 * diagnoses                        | Users of Specialized Component drugs, by age group (in years) |          |          |          |          |          |
|-------------------------------------------|-------------------------------------------------------------|----------|----------|----------|----------|----------|
|                                           | 0 to 19: 95 | 20 to 39: 273 | 40 to 59: 582 | 60 or more: 578 | p-value |
|                                           | %          | %           | %          | %         |           |           |
|Predominantly allergic asthma              | 14.7       | 7.5; 22.0   | 6.2        | 13.3      | 25.6      | 22.0; 29.2| <0.001*   |
|Chronic kidney disease stage 5             | 3.2        | 0.4; 6.7    | 8.4        | 9.7; 15.1 | 13.3      | 10.5; 16.1| 0.002*    |
|Kidney transplant status                  | 4.2        | 0.1; 8.3    | 11.4       | 6.0; 10.5 | 5.7       | 3.8; 7.6  | 0.016*    |
|Chronic viral hepatitis C                  | 0.0        | –           | 0.0        | 0.7       | 1.6       | 0.5; 2.6  | <0.001*   |
|Other seropositive rheumatoid arthritis    | 0.0        | –           | 0.0        | 0.3; 1.8  | 7.9       | 5.7; 10.1 | 5.2       | 3.4; 7.0  | <0.001*   |
|Paranoid schizophrenia                     | 9.5        | 3.5; 15.5   | 11.7       | 3.3       | 1.8; 4.7  | 0.8; 3.0  | 0.001*    |
|Seronegative rheumatoid arthritis          | 0.0        | –           | 2.2        | 0.4; 5.0  | 5.0       | 3.2; 6.8  | 2.8       | 1.4; 4.1  | 0.020*    |
|Pure hypercholesterolemia                  | 0.0        | –           | 0.0        | –         | 1.6       | 0.5; 2.6  | 6.9       | 4.8; 9.0  | <0.001*   |
|Ankylosing spondylitis                     | 0.0        | –           | 4.0        | 1.7; 6.4  | 4.5       | 2.8; 6.2  | 0.9       | 0.1; 1.6  | <0.001*   |
|Chronic viral hepatitis B without delta-agent| 0.0        | –           | 3.3        | 1.2; 5.4  | 3.4       | 2.0; 4.9  | 1.4       | 0.4; 2.3  | 0.038*    |
|Parkinson disease                          | 0.0        | –           | 0.4        | 0.4; 1.1  | 0.9       | 0.1; 1.6  | 4.8       | 3.1; 6.6  | <0.001*   |
|Hyperprolactinemia                         | 0.0        | –           | 4.8        | 2.2; 7.3  | 2.8       | 1.4; 4.1  | 0.5       | 0.1; 1.1  | 0.013*    |
|Liver transplant status                    | 11.1       | 1.0; 3.1    | 0.4        | 0.4; 1.1  | 2.1       | 0.9; 3.2  | 2.9       | 1.6; 4.3  | 0.018*    |
|Systemic lupus erythematosus with organ or system involvement | 11.1 | 1.0; 3.1 | 2.6 | 0.7; 4.5 | 2.2 | 1.0; 3.4 | 1.4 | 0.4; 2.3 | 0.505* |
|Alzheimer disease with late onset          | 0.0        | –           | 0.0        | –         | 0.0       | –         | 4.5       | 2.8; 6.2  | n.a.*     |
|Other diagnoses f                          | 70.5       | 61.2; 79.9  | 42.1       | 36.2; 48.2 | 28.0       | 24.3; 31.7 | 24.1      | 20.6; 27.5 | <0.001*   |

*ICD-10: International Statistical Classification of Diseases and Related Health Problems – 10th Revision.
*95%CI: 95% confidence interval.
*p-value from a chi-squared test for linear trend.
#p-value from a chi-squared test for heterogeneity.
*95%CI: 95% confidence interval.
**n.a.: p-value not possible.
*Other diagnoses include morbidities with prevalence lower than 1.7%.

with the national study. Corroborating the results of this study, kidney disease affects more men and older individuals. The main risk factors for kidney disease are hypertension and diabetes, which have a growing prevalence, contributing to the increased incidence of this morbidity which affects the kidneys. Kidney disease could be avoided in many cases, considering that there are medicines available for free, both in primary health care and in pharmacies accredited in the Brazilian Popular Drugstore Program, for its main risk factors, hypertension and diabetes. Hence, if individuals who had risk factors were effectively monitored, this could prevent the disease progression and the worsening of the health status, besides the suffering and, certainly, expenses with high-cost drugs.

Kidney disease is among those that represent the highest expenses with high-cost drugs, according to a national study on total expenditures of the Ministry of Health from 2000 to 2007. In this present study, among the ten most prevalent drugs, three were for kidney disease: epoetin alfa, iron hydroxide saccharate and calcitriol; the first one had the highest total monthly expense.

In this study, the prevalence of the diagnosis of kidney transplanted status is higher than what was found in the national research between 2000 and 2004. Another nationwide study about the Ministry of Health’s spending history from 2000 to 2007 showed that the drugs for transplant patients were among those with the highest financial impact. In this study, azathioprine, tacrolimus and sodium mycophenolate are among the ten most prevalent drugs, and they are used by transplant patients – including kidney –, and the latter two had the highest average monthly expense per user. In the absence of more recent studies, comparisons were made with data from the latest national studies and those data point to the same direction.

The relationship between the higher prevalence of some morbidities and the presence of PHU/FHS is
complex, as the implementation of the Family Health Strategy may be seen as recent. Higher prevalence of users taking Specialized Component drugs for chronic kidney diseases in neighborhoods with FHS may indicate higher access of those users to health services for diagnosis and effective referral to other levels of care that require the use of these drugs. In the long term, a different reality would be expected, due to the full care provided to these users by FHS teams, in order to prevent chronic health problems through effective pharmacological treatment, reducing the need for Specialized Component drugs. This hypothesis is corroborated by a study carried out with individuals with risk factors for kidney disease, such as hypertensive and diabetics people, or both, which demonstrated the following finding: before the implementation of the FHS teams, 26.5% individuals had no access to any health care service.

In the neighborhoods without FHS teams, the results may be aggravated by the lack of adequate monitoring of the individuals. Thus, among the actions of the National Policy on Mental Health, the Psychosocial Care Centers (CAPS) have a strategic role in coordinating and strengthening the care networks for these users, working together with the FHS teams in the development of therapeutic projects, aiming at the insertion and autonomy of the user in the community life. However, in the municipality of São Leopoldo-RS, there are few

---

**Table 5 – Drug expense among users of the Specialized Component of Pharmaceutical Assistance, with the ten most prevalent and the ten most expensive drugs, in the municipality of São Leopoldo-RS, 2014**

| Drugs | N  | Average monthly expense per person (BRL) | Total monthly expense (BRL) |
|-------|----|----------------------------------------|-----------------------------|
| **The most prevalent drugs** | | | |
| 1 Budesonide+formoterol fumarate 12 / 400 mcg CAP INHA | 280 | 44.33 | 12,411.77 |
| 2 Epoetin alfa 4,000 IU INJ | 175 | 216.70 | 37,922.34 |
| 3 Iron hydroxide saccharate 100 mg INJ | 129 | 15.60 | 2,012.40 |
| 4 Azathioprine 50 mg TAB | 100 | 12.78 | 1,278.00 |
| 5 Tacrolimus 1 mg CAP | 91 | 368.96 | 33,576.90 |
| 6 Ribavirin 250 mg TAB | 88 | 18.09 | 1,591.52 |
| 7 Calcitriol 1 mcg INJ | 85 | 168.96 | 14,361.48 |
| 8 Sodium mycophenolate 360 mg TAB | 80 | 384.20 | 30,735.90 |
| 9 Leflunomide 20 mg TAB | 73 | 138.60 | 10,117.80 |
| 10 Methotrexate 2.5 mg TAB | 59 | 11.61 | 685.52 |
| **Total monthly expense with the ten most prevalent drugs** | | 144,693.63 | |

| Drugs | N  | Average monthly expense per person (BRL) | Total monthly expense (BRL) |
|-------|----|----------------------------------------|-----------------------------|
| **The most expensive drugs** | | | |
| 1 Infliximab 10 mg/ml INJ | 14 | 5,178.81 | 72,503.28 |
| 2 Human immunoglobulin 5 g INJ | 3 | 4,923.96 | 14,771.88 |
| 3 Octreotide Acetate LAR 30 mg/ml INJ | 2 | 4,075.76 | 8,151.52 |
| 4 Octreotide Acetate LAR 20 mg/ml INJ | 3 | 3,019.09 | 9,057.27 |
| 5 Dornase alpha 2.5 mg INHA SOL | 8 | 2,607.90 | 20,863.20 |
| 6 Rituximab 500 mg INJ | 10 | 2,461.81 | 24,618.10 |
| 7 Interferon beta-1b 9,600,000 IU (300 mcg) INJ | 2 | 2,061.90 | 4,123.80 |
| 8 Interferon beta-1a 12,000 IU (44 mcg) INJ | 8 | 1,977.48 | 15,819.84 |
| 9 Interferon beta-1a 6,000 IU (30 mcg) INJ | 4 | 1,856.08 | 7,424.32 |
| 10 Glatiramer acetate 20 mg INJ | 7 | 1,790.00 | 12,530.00 |
| **Total monthly expense with the ten most expensive drugs** | | 189,863.21 | |

Note: An expensive medicine is that with higher financial impact, according to the monthly treatment cost per individual.
CAPS, and the existing ones are located in the central area, which impairs the access. Hence, in the absence of such care, the medicalization of those with mental and behavioral disorders may represent the only therapeutic choice available. In addition, it is possible that the small amount of active CAPS increases the costs of medications, since multi-professional monitoring may contribute to the reduction of medicines used as treatment progresses.

Despite the availability of studies to evaluate the cost of Specialized Component drugs, their comparison should be made with caution regarding the costs considered, since methodologies, time horizon and morbidities investigated differ.

In the assessment of the pharmacotherapeutic costs estimated in this study, the total monthly expenses with the most prevalent and the most expensive drugs were not very different, since the most expensive drugs were used by a smaller number of users, representing only 2.5% of Specialized Component total expenditures.

The drug budesonide + formoterol fumarate, used in the asthma treatment, although being the most prevalent, represents a small impact on total monthly expense, as the average monthly cost per user is relatively low when compared to other drugs. In the case of immunosuppressive drugs, tacrolimus and sodium mycophenolate, the first is one of immunosuppressive therapeutic innovations, whilst the latter results from the improvement of an immunosuppressive, developed in an attempt to reduce the unwanted symptoms caused by the drug in the gastrointestinal system, justifying their high-costs.

Among the most prevalent drugs, epoetin alfa had the highest total monthly expense and is indicated for the treatment of anemia associated with several morbidities, mainly kidney disease. The high prevalence of kidney disease, its wide use and its high-cost justify the values invested in the acquisition of this drug. A study conducted in Santa Catarina State (1999-2004) identified epoetin alfa as the most demanded drug. With regard to its high-cost, efforts have been made since 2006 for epoetin alfa to be produced in Brazil, since between 2000 and 2004, it was the drug which had the highest cost to SUS for kidney disease treatment.

When it comes to the most expensive drug, infliximab, a similar result was observed in a national study (2000-2004) as this drug had the second largest expense. In the comparison between this study and an economic evaluation research carried out in Paraná in 2008, individual costs have been increasing over the years, although a different methodology was used to calculate expenditure.

Biological agents, such as infliximab, have been revolutionizing the treatment of rheumatoid arthritis, especially in refractory cases to classical therapies. The use of these drugs has a great impact in the improvement of users’ quality of life, by the reduction of the disease symptoms, but with a significant increase of costs for the health system. On the other hand, there is a compensation of these costs: the reduction of disability and morbidity associated with this disease, with a favorable impact for the entire society.

Although more than a decade has elapsed since a national study (2004), which identified the ten most expensive drugs in terms of average monthly expense per individual, this study highlighted eight of the ten drugs in that study, showing that higher spending trends per individual are following the same direction. The same occurs with the drugs interferon beta and octreotide, mentioned with the program’s higher cost per individual in another study developed in the Brazilian South region.

Some limitations of this study should be highlighted. Only the cost of each medicine was considered, not the cost of the therapeutic scheme or other costs that may arise from the therapeutic choice. In addition, this study sample is composed of users of Specialized Component drugs with a request granted through administrative proceedings in 2014, allowing the generalization of results for the local population. However, similar results may be identified in other national scenarios.

In conclusion, the profile of these users indicated broad range of morbidities. Diseases such as asthma and rheumatoid arthritis are usually not preventable, that is, as the individual develops them, health policies should have to provide their clinical monitoring and medical treatment. Thus, we can highlight Specialized Component’s importance in promoting access to high-cost drugs, for individuals who, usually, would not be able to afford them. With regard to kidney disease, prevention is possible, many of these patients could be treated and learn about it in the primary health care level whilst presenting the initial risk factors, such as hypertension and diabetes, whose pharmacological treatments, once well guided by primary health care, are proven effective and at a much lower cost.
In this context, in the case of high added-value drugs, the Pharmaceutical Assistance organization should be seen as one of the essential elements, focusing from the planning of medicines to their rational use, subsidizing an efficient allocation of resources. Drugs with high total cost due to high consumption, such as epoetin alfa, should be the subject of specific planning and acquisition strategies at the lowest possible cost, avoiding the waste of public resources.1 The results of this study may support subsequent assessments of pharmacological treatments and the development of health actions, aimed at the prevention and management of future potential users of the Specialized Component of Pharmaceutical Assistance.

Authors’ Contributions

Sopelsa M reviewed the literature, developed this project, organized the database, and worked on the analysis and interpretation of data and on writing this manuscript. Motter FR contributed to the database organization and analyses. Barcellos NT and Leite HM contributed to the critical review and writing of this manuscript. Paniz VMV participated in all stages of this project, from the analysis and interpretation of data to its final writing. All authors reviewed and approved the final version of this manuscript and declared to be responsible for all aspects of this study, ensuring its accuracy and integrity.

References

1. Ministério da Saúde (BR). Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Política nacional de medicamentos [Internet]. Brasília: Ministério da Saúde; 2000 [citado 2017 jun19]. 40 p. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/politica_medicamentos.pdf
2. Brasil. Ministério da Saúde. Conselho Nacional de Saúde. Resolução nº 338, de 06 de maio de 2004. Aprova a política nacional de assistência farmacêutica. Diário Oficial da República Federativa do Brasil, Brasília (DF), 2004 maio 07; Seção 1.
3. Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Da excepcionalidade às linhas de cuidado: o componente especializado da assistência farmacêutica [Internet]. Brasília (DF): Ministério da Saúde, 2010 [citado 2017 jun 19]. 262 p. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/excepcionalidade_linhas_cuidado_ceaf.pdf
4. Brasil. Ministério da Saúde. Portaria GM/MS nº 2.577, de 27 de outubro de 2006. Aprova o componente de medicamentos de dispensação excepcional. Diário Oficial da República Federativa do Brasil, Brasília (DF), 2006 out 30; Seção I.
5. Brasil. Ministério da Saúde. Portaria GM/MS nº 1.554, de 30 de julho de 2013. Dispõe sobre as regras de financiamento e execução do componente especializado da assistência farmacêutica no âmbito do Sistema Único de Saúde (SUS). Diário Oficial da República Federativa do Brasil, Brasília (DF), 2013 jul 31; Seção I.
6. Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Componente especializado da assistência farmacêutica: inovação para a garantia do acesso a medicamentos no SUS [Internet]. Brasília (DF): Ministério da Saúde; 2014 [citado 2017 jun 19]. 164 p. Disponível em: http://portalarquivos.saude.gov.br/images/pdf/2015/janeiro/06/Livro-2-completo-para-site-com-ISBN.pdf
7. Sesso R, Lopes AA, Thomé FS, Bevilacqua JL, Romão Junior JE, Lugon J. Relatório do censo brasileiro de diálise crônica 2008. J Bras Nefrol. 2008 out-dez; 30(4):233-8.
8. Silva GD, Acúrcio FA, Cherchiglia ML, Guerra Júnior AA, Andrade EIG. Medicamentos excepcionais para doença renal crônica: gastos e perfil de utilização em Minas Gerais, Brasil. Cad Saúde Pública. 2011 fev;27(2):357-68.
9. Fundação Instituto Brasileiro de Geografia e Estatística. [Internet]. Censo Demográfico 2010 [Internet]. – 2010 [citado 2017 mar 30]. Disponível em: http://censo2010.ibge.gov.br/.
10. Centro Brasileiro de Classificação de Doenças. Classificação estatística internacional de doenças e problemas relacionados à saúde (CID-10) [Internet]. – 2015 [citado 2015 abr 6]. Disponível em: http://www.datasus.gov.br/cid10/ V2008/cid10.htm.
11. Brandão CMR, Guerra Júnior AA, Cherchiglia ML, Andrade EIG, Almeida AM, Dias da Silva G, et al. Gastos do Ministério da Saúde do Brasil com medicamentos de alto custo: uma análise centrada no paciente. Value Health. 2011 Jul-Aug; 14(5) Suppl:S71-7.
12. Acurcio FA, Brandão CMR, Guerra Júnior AA, Cherchiglia ML, Andrade IG, Almeida AM, et al. Perfil demográfico e epidemiológico dos usuários de medicamentos de alto custo no Sistema Único de Saúde. Rev Bras Estud Popul. 2009 dez;26(2):263-82.

13. Wiens A, Grochocki MC, Pontarolli DRS, Venson R, Correr CJ, Pontarolo R. Perfil dos usuários de anticitocinas disponibilizadas pelo Sistema Único de Saúde no estado do Paraná para o tratamento da artrite reumatoide. Rev Bras Reumatol. 2012 mar-abr;52(2):208-13.

14. Instituto Brasileiro de Geografia e Estatística. Pesquisa nacional por amostra de domicílios [Internet]. – 2008 [citado 2017 jun 19]. Disponível em: http://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/pnad2008/default.shtm

15. Pastorino AC, Accioly AP, Lanzellotti R, Camargo MCD, Jacob CMA, Grumach AS. Asma - aspectos clínico-epidemiológicos de 237 pacientes de um ambulatório pediátrico especializado. J Pediatri. 1998 jan-fev;74(1):49-58.

16. Moraes LSL, Barros MD, Takano OA, Assami NMC. Fatores de risco, aspectos clínicos e laboratoriais da asma em crianças. J Pediatri. 2001 nov-dez;77(6):447-54.

17. Morais-Almeida M, Pité H, Perreira AM, Nunes C, Fonseca J. Asma e rinite no idoso: estudo epidemiológico nacional. Rev Port Imunoalergologia. 2014 mar;22(1):33-42.

18. Louzada-Junior P, Souza BDB, Toledo RA, Ciconelli RM. Análise descritiva das características demográficas e clínicas de pacientes com artrite reumatoide no estado de São Paulo, Brasil. Rev Bras Reumatol. 2007 mar-abr;47(2):84-90.

19. Ferraz MB, Soarez PC, Riera R, Ciconelli RM. Conduta no diagnóstico e tratamento dos pacientes com artrite reumatoide no Brasil - respostas dos médicos a um questionário de avaliação. Acta Reum Port. 2009 jan-mar;34(1):44-51.

20. Blumenauer BTBB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2002 Jul;(3):CD003785.

21. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May;54(5):1390-400.

22. Carias CM, Vieira FS, Giordano CV, Zucchi P. Medicamentos de dispensação excepcional: histórico e gastos do Ministério da Saúde do Brasil. Rev Saúde Pública. 2011 abr;45(2):233-40.

23. Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Saúde mental no SUS: os centros de atenção psicossocial [Internet]. Brasília (DF): Ministério da Saúde; 2004 [citado 2017 jun 19]. 86 p. Disponível em: http://www.ccs.saude.gov.br/saude_mental/pdf/sm_sus.pdf

24. Santana ML, Carmagnani MI. Programa saúde da família no Brasil: um enfoque sobre seus pressupostos básicos, operacionalização e vantagens. Saúde Soc. 2001 jul;10(1):35-53.

25. Paiva DCP, Bersusa AAS, Escuder MML. Avaliação da assistência ao paciente com diabetes e/ou hipertensão pelo Programa Saúde da Família do Município de Francisco Morato, São Paulo, Brasil. Cad Saúde Pública. 2006 fev;22(2):377-85.

26. Guerra Júnior AA, Acúrcio FA, Andrade EIG, Cherchiglia ML, Cesar CC, Queiroz OV, et al. Ciclosporina versus tacrolimus no transplante renal no Brasil: uma comparação de custos. Cad Saúde Pública. 2010 jan;26(1):163-74.

27. Abbud-Filho M, Baptista MASF, Carvalho DBM, Figueiro JMG, Garcia VD, Gonçalves LFS, et al. Conversão para micofenolato de sódio em pacientes receptores de transplante renal em manutenção: análise multicêntrica retrospectiva. J Bras Transpl. 2007 out-dez;10(4):817-21.

28. Blatt CR, Farías MR. Diagnóstico do Programa de Medicamentos Excepcionais do Estado de Santa Catarina - Brasil. Lat Am J Pharm. 2007;26(5):776-83.

29. Venson R, Wiens A, Correr CJ, Otuki MF, Grochocki MC, Pontarolli DRS, et al. Avaliação econômica das anticitocinas adalimumabe, etanercepte e infliximabe no tratamento da artrite reumatoide no Estado do Paraná. Fysis. 2011;21(2):359-76.

30. Monteiro RDC, Zanini AC. Análise de custo do tratamento medicamentoso da artrite reumatoide. Rev Bras Cienc Farm. 2008 jan-mar;44(1):25-33.